Fundz
New|Fundz now works inside Claude2 min

Signals were just the beginning. Fundz is what’s next.

Only Fundz brings more than a dozen live business signals together on each company, ranks every company against your ICP, and each morning delivers the best: who to reach out to, why, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Viatris to acquire Pacira BioSciences for growth

PUBLIC · VTRSOct 08, 2026

Acquiring Company

Viatris

Acquired Company

Pacira BioSciences

Pittsburgh

Description

Viatris has reached an agreement to acquire Pacira BioSciences, which will enhance its innovative medicines strategy. This acquisition positions Viatris as a leader in non-opioid pain therapies. The move underscores Viatris's commitment to addressing pain management and improving patient outcomes. The transaction is expected to drive significant growth for both companies.

Company Information

Company

Viatris

Location

Pittsburgh, Pennsylvania, United States

About

Viatris is a global healthcare and pharmaceutical corporation based in Canonsburg, Pennsylvania. Formed in November 2020 from the merger of Mylan and Pfizer's Upjohn division, Viatris aims to enhance access to medicines worldwide. The company operates in over 165 countries and territories, delivering high-quality medicines to patients. Viatris offers a diverse portfolio that includes generics, established brands, biosimilars, and innovative specialty medicines. Their product range encompasses oral solid doses, injectables, complex dosage forms, and active pharmaceutical ingredients. The company addresses various therapeutic areas, such as cardiovascular health, oncology, infectious diseases, and women's healthcare. In addition to its products, Viatris provides support services like diagnostic clinics and educational seminars to help patients manage their health effectively. With a workforce of around 45,000 employees, Viatris serves a wide array of customers, including hospitals, clinics, and pharmacies, across multiple market segments.

Fundz sees it the moment Viatris makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Viatris's next move

Learn about Strategic plan

Frequently asked

Who acquired Pacira BioSciences?

Pacira BioSciences was acquired by Viatris, based in Pittsburgh. The deal was reported on October 8, 2026. Viatris is a global healthcare and pharmaceutical corporation based in Canonsburg, Pennsylvania. Viatris is publicly traded (VTRS).

When did Viatris acquire Pacira BioSciences?

Viatris's acquisition of Pacira BioSciences was reported on October 8, 2026. Viatris has reached an agreement to acquire Pacira BioSciences, which will enhance its innovative medicines strategy. This acquisition positions Viatris as a leader in non-opioid pain therapies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Pacira BioSciences do?

Pacira BioSciences is a leading provider of non-opioid pain management solutions that support patients’ recovery. They are committed to advancing surgical care through innovative and patient-centered products. It is publicly traded (PCRX).

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.